Skip to content

Revenue at other companies

Monro, Inc. logo
Monro, Inc.MNRO
$273.84M-7.2%
DJT
Trump Media & Technology GroupDJT
$871.2K+6.1%
ADMA Biologics logo
ADMA BiologicsADMA
$114.49M-0.3%
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$666.95M-53.0%
Lesaka Technologies, Inc. logo
Lesaka Technologies, Inc.LSAK
$183.05M+13.4%
Ollie's Bargain Outlet Holdings, Inc. logo
Ollie's Bargain Outlet Holdings, Inc.OLLI
$658.93M+14.2%

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity-0.3×
Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's revenue?
CytomX Therapeutics (CTMX) reported revenue of $10.26M in Q1 2026.
How has CytomX Therapeutics's revenue changed year-over-year?
CytomX Therapeutics's revenue decreased by 79.9% year-over-year, from $50.92M to $10.26M.
What is the long-term trend for CytomX Therapeutics's revenue?
Over 4 years (2021 to 2025), CytomX Therapeutics's revenue has grown at a 19.5% compound annual growth rate (CAGR), from $37.31M to $76.2M.